RE:RE:RE:RE:RE:RE:RE:The recent Option Grant.Let's state it all in a very simple way, pof.
I think it likely that Bioasis is down to one company for xB3-001 and possibly for the other xB3 cancer drugs. I think it possible that an announcement of such, and announcements relating to xB3-004, xB3-progranulin and other licensing and partnership agreements, will be revealed in the weeks and months ahead. I believe the execution of this storyboard is intended to move Bioasis to a painless, even triumphant, listing on NASDAQ.
As I've written before, the Cresence announcement may have been the first publicly revealed strategic event to position Bioasis as a suitable and promotable clinical stage company for listing on NASDAQ. Being "clinical stage" is likely more important to Bioasis than the EGF program is. The optics of actually being clinical stage may be intended to cause investors to rightly assume that every Bioasis drug, and those in the hands of partners, are future clinical assets and are not just words on a corporate presentation.
If things of these magnitudes are not in the works then there was no reason for Bioasis to have voluntarily put NASDAQ on the table and to discuss it publicly. In my opinion, the NASDAQ announcement and public discussion were acts of high confidence.
jd